13F Filings/ORBIMED ADVISORS LLC

ORBIMED ADVISORS LLC

Hedge FundCIK0001055951LocationNEW YORK, NY 10022, United States

Long U.S. equity positions disclosed to the SEC on Form 13F-HR.

Latest filingQ2 2026Quarter ended30 Jun 2026Filed14 Aug 2026
Firm profile · Form ADV
SEC adviser registration

OrbiMed is an investment manager exclusively focused on the healthcare sector, managing approximately $13.6 billion on a discretionary basis for 32 clients as of December 31, 2025. The firm provides discretionary investment management services to U.S. and non-U.S. public and private funds, utilizing strategies that involve evaluating companies within the global healthcare sector, including pharmaceutical, biotechnology, medical device, and healthcare services. These strategies generally include investments in securities of U.S. and non-U.S. public and/or private companies within the healthcare sector, subject to each client's investment program.Summarised from the firm’s Form ADV Part 2A brochure.

CRD
118608 · 801-61046
Portfolio Turnover
23%
Of book traded, QoQ
Positions
129
Long U.S. equities
Top 10 Concentration
42%
Of reported value
QoQ Change
$351.4M
Value change
Assets under management
Form ADV RAUM · client mix · 13F over time
Regulatory AUM
$20.6B
Form ADV, as of Mar 2026
100% discretionary ($20.6B)
By client type
Pooled investment vehicles: $20.6B (100.0%) · 32 clients
Pooled investment vehicles
$20.6B · 100%
13F AUM over time
$5.4B
Q2 ’26 · 13F AUM
43%
37 quarters
Reported Holdings
Q2 2026 · upgrade to Pro for past quarters
★ Position spotlightEWTXEDGEWISE THERAPEUTICS INC · 11.7% of bookThis highlighted stock and its 1Y chart are public
Loading position history…
SecuritySharesMarket ValueEst. CostLast PxEst. Return% PortfolioΔ SharesAction
EDGEWISE THERAPEUTICS INC
EWTX· Health Care
15.52MSH$630.5M~$40.63$43.076.0%11.7%Unchanged
ENLIVEN THERAPEUTICS INC
ELVN· Health Care
6.78MSH$343.9M~$50.75$59.3216.9%6.4% 14.9%Reduced
ELI LILLY & CO
LLY· Health Care
258KSH$309.3M~$1199.43$1149.364.2%5.7% 8.9%Added
MBX BIOSCIENCES INC
MBX· Health Care
3.43MSH$189.3M~$55.20$61.7211.8%3.5% 5.7%Reduced
SINOVAC BIOTECH LTD
2.72MSH$184.5M~$67.853.4%Unchanged
ASTRAZENECA PLC
916KSH$171.1M~$186.833.2% 36.6%Added
STRUCTURE THERAPEUTICS INC
GPCR· Health Care
2.21MSH$118.6M~$53.67$47.3411.8%2.2% 49.7%Added
SIONNA THERAPEUTICS INC
SION· Health Care
2.56MSH$112.4M~$43.99$7.1883.7%2.1% 27.6%Reduced
CORVUS PHARMACEUTICALS INC
CRVS· Health Care
7.17MSH$107.0M~$14.94$14.393.7%2.0%Unchanged
ARRIVENT BIOPHARMA INC
AVBP· Health Care
3.03MSH$105.2M~$34.74$30.9510.9%1.9%Unchanged
EWTXEDGEWISE THERAPEUTICS INCUnchanged
$630.5M· 11.7%· 15.52M SH· · cost $40.63· last $43.07· 6.0%
Health Care · COM · DFND
ELVNENLIVEN THERAPEUTICS INCReduced
$343.9M· 6.4%· 6.78M SH· 14.9%· cost $50.75· last $59.32· 16.9%
Health Care · COM · SOLE
LLYELI LILLY & COAdded
$309.3M· 5.7%· 258K SH· 8.9%· cost $1199.43· last $1149.36· 4.2%
Health Care · COM · SOLE
MBXMBX BIOSCIENCES INCReduced
$189.3M· 3.5%· 3.43M SH· 5.7%· cost $55.20· last $61.72· 11.8%
Health Care · COM · SOLE
SINOVAC BIOTECH LTDUnchanged
$184.5M· 3.4%· 2.72M SH· · cost $67.85
SHS · SOLE
ASTRAZENECA PLCAdded
$171.1M· 3.2%· 916K SH· 36.6%· cost $186.83
ORD · SOLE
GPCRSTRUCTURE THERAPEUTICS INCAdded
$118.6M· 2.2%· 2.21M SH· 49.7%· cost $53.67· last $47.34· 11.8%
Health Care · SPONSORED ADS · DFND
SIONSIONNA THERAPEUTICS INCReduced
$112.4M· 2.1%· 2.56M SH· 27.6%· cost $43.99· last $7.18· 83.7%
Health Care · COM · SOLE
CRVSCORVUS PHARMACEUTICALS INCUnchanged
$107.0M· 2.0%· 7.17M SH· · cost $14.94· last $14.39· 3.7%
Health Care · COM · SOLE
AVBPARRIVENT BIOPHARMA INCUnchanged
$105.2M· 1.9%· 3.03M SH· · cost $34.74· last $30.95· 10.9%
Health Care · COM · SOLE
110 of 129
1 / 13
Sector Breakdown
Q2 2026
Health Care86.6% · $4.7B
Unclassified13.4% · $722.7M